Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Semaglutide and Tesamorelin — mechanism, side effects, legal status, and pricing.
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic (SubQ, type 2 diabetes), Wegovy (SubQ, chronic weight management and cardiovascular risk reduction in obesity), and Rybelsus (oral, type 2 diabetes). It is a synthetic analog of native GLP-1 with a fatty-acid (C18 diacid) side chain that enables albumin binding, giving it a ~165-hour half-life suitable for once-weekly injection.
Tesamorelin (Egrifta / Egrifta SV) is a stabilized analog of human GHRH(1-44) with a trans-3-hexenoic acid moiety at the N-terminus that protects against protease degradation. FDA-approved in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, it is the only FDA-approved GHRH analog for this indication. Off-label use for general body composition and visceral fat reduction in non-HIV populations is common but outside the approved label.
Semaglutide
Tesamorelin
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Semaglutide
Tesamorelin
COA corpus from Disclosed Labs — independently tested batches only.
Semaglutide
128
COAs
99.6%
Avg purity
13
Labs
Tesamorelin
175
COAs
99.5%
Avg purity
14
Labs
Tesamorelin is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Semaglutide remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
The STEP program (STEP 1–8) showed average weight loss of roughly 15% of body weight over 68 weeks with weekly 2.4 mg semaglutide (STEP 1: Wilding et al., NEJM 2021, PMID 33567185). The SUSTAIN program established A1c and cardiovascular benefit in type 2 diabetes. The PIONEER program established efficacy of oral semaglutide (Rybelsus) versus placebo, sitagliptin, empagliflozin, and liraglutide (PIONEER 4, PMID 31186120). The SELECT trial (Lincoff et al., NEJM 2023, PMID 37952131) showed a 20% relative reduction in major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease but without diabetes, leading to an expanded Wegovy indication.
FDA approval (NDA 022505) was based on two Phase 3 trials reported by Falutz et al. (NEJM, 2007; PMID 18057338) and the pooled 52-week safety extension, showing ~15-18% reduction in visceral adipose tissue with improved triglycerides in HIV patients with abdominal fat accumulation. Stanley et al. (JAMA, 2014; PMID 25038357) demonstrated concurrent reductions in visceral and liver fat (NAFLD). Baker et al. (Arch Neurol, 2012; PMID 22869065) reported favorable effects on executive function in older adults with and without mild cognitive impairment at 1 mg/day for 20 weeks — note this cognition signal was in MCI / healthy older adults, not specifically APOE4-positive individuals. Current label dose is 1.4 mg SubQ daily (Egrifta SV); legacy Egrifta used 2 mg/day. Off-label use for general body composition in non-HIV populations is common but outside the FDA label.
Key references
Semaglutide (Metabolic) and Tesamorelin (Performance) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs